A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
109actual
Sites
132
Countries
Argentina, Belgium, Brazil +21
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-12 | actual | When the study began enrolling |
| Primary completion | 2026-06-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Polyneuropathy, Inflammatory Demyelinating, Chronic
Interventions
- Drug: Riliprubart — also filed as SAR445088
- Drug: Placebo
- Drug: Riliprubart — also filed as SAR445088
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants experiencing a response
measured Baseline to week 24
Percentage of participants randomized to riliprubart with lasting response
measured Baseline to week 48
Percentage of participants randomized to placebo who experience a response
measured Week 24 to week 48
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed